Date: 2011-06-22
Type of information:
phase: 1b
Announcement:
Company: Medivir (Sweden) Tibotec Pharmaceuticals (J&J Group - USA)
Product: TMC649128
Action mechanism: TMC649128 is a nucleoside NS5B polymerase inhibitor developed in collaboration with Tibotec Pharmaceuticals. TMC649128 has demonstrated an attractive pre-clinical profile and displays in vitro activity across multiple HCV genotypes and a high genetic barrier to resistance.
Disease: Genotype-1 Hepatitis C Virus infection
Therapeutic area: Infectious diseases
Country:
Trial
details: The TMC649128 phase Ib study that now is underway is a double-blind, randomized and placebo-controlled trial in genotype 1 HCV-infected patients to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of multiple ascending doses of TMC649128 given as monotherapy and in combination with pegylated interferon and ribavirin.
Latest
news: Medivir has announced the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection. It is anticipated that TMC649128 will be used in combination with other HCV direct acting antiviral agents, given its high genetic barrier to resistance and antiviral activity across multiple HCV genotypes/
